GlaxoSmithKline to discontinue Zinetac tablets in India

By: |
Published: May 21, 2020 7:10:20 PM

GlaxoSmithKline Pharmaceuticals on Thursday said it has decided to discontinue production and sale of Zinetac tablets, used to treat and prevent heartburn, in the country.

The company has made a decision to discontinue the manufacture and supply of Zinetac tablets (150 mg and 300 mg products) manufactured in India.

GlaxoSmithKline Pharmaceuticals on Thursday said it has decided to discontinue production and sale of Zinetac tablets, used to treat and prevent heartburn, in the country.

The company has made a decision to discontinue the manufacture and supply of Zinetac tablets (150 mg and 300 mg products) manufactured in India and will in due course request cancellation of the marketing authorisation associated with the drug, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.

In the coming months, the drug firm will work closely with the regulatory authorities, it added. The drug firm was contacted by regulatory authorities regarding the detection of cancer causing N-Nitrosodimethylamine (NDMA) in Zinetac (ranitidine) products.

Based on the information received and correspondence with regulatory authorities, the company made the decision in September 2019 to initiate a voluntary recall of all ranitidine products in all markets of  as a precautionary action.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Delhi Govt takes over 5 hotels for Covid wards
2Lockdown extension: States to have more say in Lockdown 5.0, Centre likely to retain limited role
3Lockdown in West Bengal: CM Mamata announces relaxations from June 1